DexCom Balanced Scorecard
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
Go Beyond the Preview – Access the Full Balanced Scorecard
This DexCom Balanced Scorecard Analysis helps you evaluate the company's financial, customer, internal process, and learning and growth priorities in one clear framework. The page already shows a real preview of the actual analysis, so you can review the content and format before buying. Purchase the full version to get the complete ready-to-use report.
Benefits
Outcome Link
DexCom's scorecard should link CGM use to real outcomes: higher time in range, lower A1C, and fewer hypoglycemia events. In CGM studies, time in range often improves by 10 to 15 points, and A1C can drop by 0.4 to 0.6 percentage points. That keeps the focus on whether 24/7 glucose data is changing diabetes control, not just whether sensors are shipping.
Patient Value
DexCom G7 gives 10-day wear, a 60-minute warmup, and real-time alerts, so patient value shows up in faster action and fewer fingerstick checks. In 2025, the scorecard should track alert response time, daily active users, and the drop in strip use to show whether people act sooner. If alert use rises and fingerstick testing falls, DexCom is improving daily diabetes care.
Quality Focus
DexCom's Quality Focus scorecard can track sensor accuracy, app uptime, and complaint rates in one place, which matters because a CGM is used 24/7. In 2025, that kind of control helps DexCom spot failures fast and protect trust when every missed alert or outage can affect daily diabetes care. Keeping these metrics tight supports better product quality and lower support load.
Launch Discipline
Launch discipline matters at DexCom because it keeps R&D, manufacturing, regulatory, and support moving on one release plan. In 2025, DexCom pushed the G7 15-day sensor, so software, sensor design, and supply must line up fast to protect user experience. That is key in CGM, where even one delayed update can hit adherence, claims, and revenue.
Clinician Use
DexCom can use the scorecard to track clinician onboarding, prescription conversion, and remote-sharing use, so it can see if clinics are moving from trial to routine CGM care. In 2025, that matters because Dexcom still had to turn recent launches into repeat prescribing, not just first orders. Remote sharing also shows whether clinicians are using the platform for follow-up, which can support faster care decisions and stickier adoption.
DexCom G7: Better Control, Less Friction
DexCom's benefits scorecard should show whether CGM improves diabetes control and lowers friction. In 2025, G7's 10-day wear, 60-minute warmup, and real-time alerts support faster action, while CGM studies still show about 0.4 to 0.6 A1C drop and 10 to 15 point time-in-range gains.
| Metric | 2025 signal |
|---|---|
| A1C | Down 0.4-0.6 pts |
| Time in range | Up 10-15 pts |
| G7 wear | 10 days |
| Warmup | 60 minutes |
What is included in the product
Detailed Word Document
Editable Excel File
Drawbacks
Metric Creep
DexCom can fall into metric creep when it tracks too many KPIs across product, clinical, service, and reimbursement work. That blurs the few numbers that really move choices, especially in a business that had already crossed the $4 billion revenue mark by FY2025. One clean scorecard beats a crowded one.
Attribution Noise
Attribution noise makes DexCom's effect on A1C and time in range hard to isolate, because diet, insulin dose changes, and physician coaching can move results just as much as the sensor. In practice, a 0.5 to 1.0 point A1C shift can come from care changes outside the device, so outcome gains do not map cleanly to DexCom alone.
This weakens balanced scorecard reads in 2025, since the metric mix can overstate product impact when patients improve for several reasons at once.
Data Silos
DexCom's quality, finance, customer support, and payer data often live in separate systems, so the Balanced Scorecard can lag behind real events. That matters when a company serving millions of CGM users needs near-real-time reads on warranty claims, reimbursement, and support costs. In FY2025, fragmented data can hide the link between quality issues and margin pressure until after the quarter closes.
Lag Risk
Lag risk is real because scorecards update after the fact, not in real time. A sensor fault, app outage, or supply slip can reach users before management sees it in the next report. For DexCom, that delay matters because even brief CGM disruptions can hit adherence, renewals, and trust fast. So the scorecard can show green while users are already feeling the pain.
Build Cost
Build cost is a real drawback for DexCom because a credible Balanced Scorecard needs analytics, IT links, and governance, not just KPI charts. For a medical device company, that means spending time and money on data systems, dashboard upkeep, and review cadence before any clinical or operating gain shows up. If the scorecard does not lift sensor quality, reimbursement, or execution, the overhead becomes a drag on margins rather than a value driver.
DexCom's FY2025 Results Still Blur Product Impact
DexCom's scorecard can still blur cause and effect in FY2025: revenue topped $4 billion, but A1C and time-in-range gains also depend on insulin dosing, diet, and clinician follow-up. That makes product impact hard to isolate. It also adds lag, since data often arrives after the sensor, support, or reimbursement issue has already hit users.
| FY2025 signal | Drawback |
|---|---|
| $4.0B+ revenue | Metric creep risk |
| Multi-source outcomes | Attribution noise |
Get Your Copy
DexCom Reference Sources
This DexCom Balanced Scorecard Analysis preview is the exact document the customer will receive after purchase. Nothing is altered or summarized – what you see here is pulled directly from the full report. Once purchased, the complete, detailed version becomes available for download.
Frequently Asked Questions
It measures whether CGM usage is creating clinical value. The best indicators are 24/7 readings, time in range, A1C change, and low-glucose alerts because DexCom's products are designed to replace spot-checking with continuous data. Those metrics show both user engagement and health impact in the same dashboard.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site - including articles or product references - constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.